Nov 4
2022
Phanes Therapeutics to present at BioFuture™ 2022
Company's CEO to present its innovative oncology pipeline and proprietary bispecific antibody technology platforms SAN DIEGO, Nov. 4, 2022 /PRNewswire/ -- Phanes...
Read More
Oct 14
2022
Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers
SAN DIEGO, Oct. 14, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, announced today that...
Read More
Aug 23
2022
Phanes Therapeutics announces first patient dosed in phase 1 study of PT199 for advanced solid tumors
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Aug 2
2022
Phanes Therapeutics’ anti-CD47 antibody patent granted in the US
SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Jul 1
2022
Phanes Therapeutics’ PT886 granted Orphan Drug designation for the treatment of pancreatic cancer by the FDA
SAN DIEGO, June 30, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Jun 21
2022
Phanes Therapeutics’ PT217 receives Orphan Drug designation for small cell lung cancer from the FDA
SAN DIEGO, June 21, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Jun 15
2022
Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers
SAN DIEGO, June 15, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical...
Read More
Apr 21
2022
Phanes Therapeutics revealed manufacturing validation of its bispecific technology platforms PACbody™ and SPECpair™ at AACR 2022
SAN DIEGO, April 20, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More
Apr 13
2022
Phanes Therapeutics’ anti-CD73 antibody patent granted in the US
SAN DIEGO, April 12, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More
Mar 23
2022
Phanes Therapeutics announces FDA IND clearance for PT199, a next generation monoclonal antibody against human CD73
SAN DIEGO, March 22, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology...
Read More
